Dose expansion of SX-682 alone and with decitabine for myelodysplastic syndromes (MDS)
Official title: A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients
Funded at Syntrix Biosystems, INC. · NIH-11324659 · Data updated 2026-11-12
A study to test higher doses of SX-682 alone and with decitabine in people with myelodysplastic syndromes to see if this combination can help control the disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Syntrix Biosystems, INC. NIH-funded |
| Lab location | 1 site (Auburn, United States) |
| Project start | May 1, 2025 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $740,293 |
| NIH project number | 5R44CA291622-03 |
| Project ID | NIH-11324659 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with myelodysplastic syndromes who are candidates for hypomethylating agent therapy and may benefit from CXCR1/2-targeted strategies.
✕Less likely to help
Patients whose disease does not respond to CXCR1/2 targeting or who experience intolerable adverse effects may not benefit.
What this research studies
This project looks at using SX-682, with or without the drug decitabine, in patients diagnosed with myelodysplastic syndromes that may progress to leukemia. Researchers will monitor safety, tolerability, and initial signals of effectiveness in a small group of participants over the study period. The aim is to determine whether adding SX-682 to standard treatment can better control blood cell counts and disease progression. Participants will undergo regular checkups, blood tests, and other necessary assessments during the trial. Results from this early-phase study could guide future trials and potential new treatment options for MDS patients.
Why it matters
Potential benefit: If successful, patients with MDS might gain more effective treatment options that could improve blood counts and delay progression to leukemia.
How similar studies have gone: Earlier studies in similar targeted approaches have shown safety signals and biological activity, but this exact combination in MDS is exploratory and requires confirmation.
Where this research is happening
-
Syntrix Biosystems, INC.
Auburn, United States Active
Researchers
- Principal investigator: Schuler, Aaron D — Syntrix Biosystems, INC.
- Study coordinator: Schuler, Aaron D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.